Stocksigma LogoStocksigma Logo

Ind-Swift Laboratories Reports Strong Q2 FY27 Results Driven by Formulations Shift

Ind-Swift Laboratories reported robust standalone Q2 FY27 performance, with operating income growing 50.15% YoY to ₹234.89 crore and operating EBITDA

Ind-Swift Laboratories Reports Strong Q2 FY27 Results Driven by Formulations Shift

Ind-Swift Laboratories Ltd · Press Release · 30 Oct 2026, 11:21 pm

Ind-Swift Laboratories Reports Strong Q2 FY27 Results Driven by Formulations Shift Ind-Swift Laboratories reported robust standalone Q2 FY27 performance, with operating income growing 50.15% YoY to ₹234.89 crore and operating EBITDA surging nearly 5x YoY to ₹42.33 crore, expanding margins by 1,256 bps YoY to 18.02%. PAT rose 3.54x YoY to ₹31.03 crore with a 13.21% margin. Sequentially, revenue and operating EBITDA grew 26.23% and 27.02% QoQ, respectively. Growth was driven by operational scaling in finished dosage formulations, expanding CDMO partnerships, and raw material cost efficiencies, supported by a net-debt-free balance sheet.

Original exchange filing (PDF)

More announcements from Ind-Swift Laboratories Ltd

All Ind-Swift Laboratories Ltd announcements